Skip to main content
KPC PHARMACEUTICALS, INC. logo

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 ISIN · CNE0000015P8 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 2,727 across all filing types
Latest filing 2023-01-19 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

https://en.kpc.com.cn/

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团关于十届董事会、监事会改组工作完成暨控制权发生变更的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the completion of the reorganization of the 10th Board of Directors and Supervisory Board of Kunming Pharmaceutical Group Co., Ltd., including changes in the controlling shareholder and actual controller. It details resignations, new appointments, and election results of board members and supervisors. There is no financial data or report content, but rather a formal disclosure of management and board changes. This fits the category of Board/Management Information (MANG). The document length is short and focused on governance changes, not a full report or financial statement.
2023-01-19 Chinese
昆药集团2023年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as the "2023 First Extraordinary General Meeting (EGM) Meeting Materials" for KPC Pharmaceuticals, Inc. It contains detailed agenda items, voting procedures, and explanations of proposals to be voted on by shareholders. The content includes descriptions of amendments to the company's articles of association, estimates of related party transactions for 2023, and election of board and supervisory committee members. The document is clearly a set of materials prepared for a shareholders' meeting, including detailed information to inform shareholders for decision-making and voting. It is not a report of voting results, nor a brief announcement, nor a transcript of a call. It is not an annual or quarterly financial report, nor an audit or legal proceeding report. The document fits the definition of "Presentations and materials shared during the Annual General Meeting (AGM)" or in this case, an Extraordinary General Meeting (EGM). Since the category AGM-R covers presentations and materials shared during general meetings, this document is best classified as AGM Information (AGM-R). The document length is substantial (15,000 characters), and it contains detailed meeting materials, not just an announcement or summary, so it is not RPA or RNS. Therefore, the classification is AGM-R with high confidence.
2023-01-11 Chinese
昆药集团股东减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is an announcement regarding a shareholder's plan to reduce their holdings in the company. It details the shareholder's current holdings, the planned reduction amount, methods, timing, and associated risks. There is no financial data, no report attached or referenced as being published, and no mention of an annual or interim report. The content fits the description of a Major Shareholding Notification, which involves notifying changes in significant share ownership levels or plans to reduce holdings. Therefore, the appropriate classification is Major Shareholding Notification (MRQ). The document length is short and focused solely on the shareholding reduction plan, confirming it is not a full report or other type of filing.
2023-01-06 Chinese
昆药集团关于对外担保的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the progress of external guarantees provided by Kunming Pharmaceutical Group Co., Ltd. It includes specifics about the guarantee amounts, the guaranteed parties (subsidiaries), financial data of the guaranteed company, and board opinions on the guarantee plan. The document is an announcement about a financing-related activity (providing guarantees to subsidiaries to support financing needs). It is not a full financial report, audit report, or earnings release. It is also not a regulatory certification or a report publication announcement. The content fits best under Capital/Financing Update (CAP) as it relates to financing activities and guarantees provided by the company to support its subsidiaries' financing.
2023-01-04 Chinese
昆药集团十届十一次监事会决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the supervisory board (监事会) of Kunming Pharmaceutical Group Co., Ltd. It details the passing of several proposals during a supervisory board meeting, including nominations for supervisory board members and approval of estimated related-party transactions for 2023. The document includes voting results and mentions that some proposals require shareholder meeting approval. The content is about board/management decisions and resolutions rather than financial results, audit reports, or regulatory filings. It is not a full annual or interim report, nor is it a voting result announcement from a shareholder meeting. Therefore, the document fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the company's board or senior management bodies.
2023-01-03 Chinese
昆药集团股份有限公司章程
Governance Information Classification · 100% confidence The document is titled '昆药集团股份有限公司章程' which translates to 'Articles of Association of KPC Pharmaceuticals, Inc.' It contains detailed chapters on company governance, shareholder rights, board structure, share issuance, share transfer, and other corporate governance matters. The content includes legal references to company law, securities law, and governance codes, and it is a comprehensive internal governance document. It is not a financial report, earnings release, or announcement but a governance document outlining the company's internal rules and structure. Therefore, the appropriate classification is Governance Information (CGR). The document length (15,000 characters) and detailed content confirm it is the full governance document, not just an announcement or summary.
2023-01-03 Chinese

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.